CR20170507A - Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos. - Google Patents
Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos.Info
- Publication number
- CR20170507A CR20170507A CR20170507A CR20170507A CR20170507A CR 20170507 A CR20170507 A CR 20170507A CR 20170507 A CR20170507 A CR 20170507A CR 20170507 A CR20170507 A CR 20170507A CR 20170507 A CR20170507 A CR 20170507A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- iii
- growth factor
- factor receptor
- epidermal
- Prior art date
Links
- 102000009465 Growth Factor Receptors Human genes 0.000 title 1
- 108010009202 Growth Factor Receptors Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 102000003735 Mesothelin Human genes 0.000 abstract 1
- 108090000015 Mesothelin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En el presente documento se proporcionan composiciones y métodos para desencadenar una respuesta inmunitaria en un sujeto. En particular, la presente divulgación se refiere a proteínas de fusión que comprenden un polipéptido de la variante III del receptor de factor de crecimiento epidérmico (EGFRvIII) y un polipéptido de mesotelina, y a métodos para desencadenar una respuesta inmunitaria usando células hospedadoras que comprenden moléculas de ácido nucleico que codifican dichas proteínas de fusión. En algunas realizaciones, las moléculas de ácido nucleico pueden codificar una proteína de fusión EGFRvIII-mesotelina que comprende una secuencia de aminoácidos que es al menos i) un 90% idéntica, ii) un 95% idéntica, o iii) un 99% idéntica a EGFRvIIIx5-mesotelina35-622 tal como se expone en la SEQ ID NO: 8.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562146559P | 2015-04-13 | 2015-04-13 | |
| US201562243397P | 2015-10-19 | 2015-10-19 | |
| PCT/US2016/027136 WO2016168198A1 (en) | 2015-04-13 | 2016-04-12 | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20170507A true CR20170507A (es) | 2018-02-13 |
Family
ID=55809232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20170507A CR20170507A (es) | 2015-04-13 | 2016-04-12 | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10105427B2 (es) |
| EP (1) | EP3283509A1 (es) |
| JP (1) | JP6782253B2 (es) |
| KR (1) | KR20180002640A (es) |
| CN (1) | CN107750256A (es) |
| AU (1) | AU2016247887A1 (es) |
| BR (1) | BR112017022076A2 (es) |
| CA (1) | CA2982533A1 (es) |
| CO (1) | CO2017011431A2 (es) |
| CR (1) | CR20170507A (es) |
| EA (1) | EA201792274A1 (es) |
| EC (1) | ECSP17075380A (es) |
| HK (2) | HK1250730A1 (es) |
| IL (1) | IL254957A0 (es) |
| MA (1) | MA44379A (es) |
| MX (1) | MX2017013174A (es) |
| PH (1) | PH12017502080A1 (es) |
| SG (1) | SG11201708360TA (es) |
| SV (1) | SV2017005545A (es) |
| TW (1) | TW201710285A (es) |
| UY (1) | UY36616A (es) |
| WO (1) | WO2016168198A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018512165A (ja) | 2015-04-13 | 2018-05-17 | アデュロ バイオテック，インコーポレイテッド | 癌の治療のための免疫原性融合タンパク質 |
| KR20180002640A (ko) | 2015-04-13 | 2018-01-08 | 아두로 바이오테크, 인코포레이티드 | 표피 성장 인자 수용체 변형 iii-메소텔린 융합체 및 이를 이용하는 방법 |
| IL305238A (en) | 2015-12-16 | 2023-10-01 | Gritstone Bio Inc | Identification of neoantigens, preparation, and use |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830702A (en) | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
| US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| DE69532767T2 (de) | 1994-11-28 | 2004-08-12 | Thomas Jefferson University | Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III |
| EP1303299B1 (en) | 2000-03-29 | 2010-07-28 | The Trustees of The University of Pennsylvania | Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens |
| US20050175625A1 (en) | 2002-07-12 | 2005-08-11 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| CN102220423A (zh) | 2002-08-20 | 2011-10-19 | 千年药品公司 | 用于鉴定,评估,预防和治疗子宫颈癌的组合物,试剂盒及方法 |
| EP1592442A2 (en) | 2003-02-06 | 2005-11-09 | Cerus Corporation | Modified free-living microbes, vaccine compositions and methods of use thereof |
| CA2515369C (en) | 2003-02-06 | 2015-03-31 | Cerus Corporation | Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof |
| US20050118186A1 (en) | 2003-06-17 | 2005-06-02 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in compositions for various types of cancers |
| US7935804B2 (en) | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
| DK1991263T3 (en) | 2006-03-01 | 2015-03-30 | Aduro Biotech | Prepared listeria and methods of use thereof |
| WO2007117371A2 (en) | 2006-03-01 | 2007-10-18 | Anza Therapeutics, Inc. | Engineered listeria and methods of use thereof |
| CN103415620B (zh) | 2010-11-17 | 2016-10-12 | 艾杜罗生物科技公司 | 诱导针对EGFRvIII的免疫应答的方法和组合物 |
| AU2013370210B2 (en) * | 2012-12-27 | 2018-06-14 | Aduro Biotech, Inc. | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
| US9388243B2 (en) | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
| KR20180002640A (ko) | 2015-04-13 | 2018-01-08 | 아두로 바이오테크, 인코포레이티드 | 표피 성장 인자 수용체 변형 iii-메소텔린 융합체 및 이를 이용하는 방법 |
| JP2018512165A (ja) | 2015-04-13 | 2018-05-17 | アデュロ バイオテック，インコーポレイテッド | 癌の治療のための免疫原性融合タンパク質 |
-
2016
- 2016-04-12 KR KR1020177031486A patent/KR20180002640A/ko unknown
- 2016-04-12 CN CN201680028967.8A patent/CN107750256A/zh active Pending
- 2016-04-12 UY UY0001036616A patent/UY36616A/es not_active Application Discontinuation
- 2016-04-12 SG SG11201708360TA patent/SG11201708360TA/en unknown
- 2016-04-12 EP EP16718812.7A patent/EP3283509A1/en not_active Withdrawn
- 2016-04-12 BR BR112017022076-8A patent/BR112017022076A2/pt not_active Application Discontinuation
- 2016-04-12 CR CR20170507A patent/CR20170507A/es unknown
- 2016-04-12 WO PCT/US2016/027136 patent/WO2016168198A1/en active Application Filing
- 2016-04-12 EA EA201792274A patent/EA201792274A1/ru unknown
- 2016-04-12 CA CA2982533A patent/CA2982533A1/en not_active Abandoned
- 2016-04-12 MX MX2017013174A patent/MX2017013174A/es unknown
- 2016-04-12 US US15/097,178 patent/US10105427B2/en not_active Expired - Fee Related
- 2016-04-12 JP JP2017554395A patent/JP6782253B2/ja not_active Expired - Fee Related
- 2016-04-12 MA MA044379A patent/MA44379A/fr unknown
- 2016-04-12 AU AU2016247887A patent/AU2016247887A1/en not_active Abandoned
- 2016-04-12 TW TW105111337A patent/TW201710285A/zh unknown
-
2017
- 2017-10-09 IL IL254957A patent/IL254957A0/en unknown
- 2017-10-13 SV SV2017005545A patent/SV2017005545A/es unknown
- 2017-11-07 CO CONC2017/0011431A patent/CO2017011431A2/es unknown
- 2017-11-13 EC ECIEPI201775380A patent/ECSP17075380A/es unknown
- 2017-11-16 PH PH12017502080A patent/PH12017502080A1/en unknown
-
2018
- 2018-08-06 HK HK18110071.1A patent/HK1250730A1/zh unknown
- 2018-08-10 HK HK18110280.8A patent/HK1250992A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017022076A2 (pt) | 2018-08-14 |
| SG11201708360TA (en) | 2017-11-29 |
| JP6782253B2 (ja) | 2020-11-11 |
| HK1250730A1 (zh) | 2019-01-11 |
| US10105427B2 (en) | 2018-10-23 |
| EP3283509A1 (en) | 2018-02-21 |
| CO2017011431A2 (es) | 2018-01-16 |
| CA2982533A1 (en) | 2016-10-20 |
| JP2018512166A (ja) | 2018-05-17 |
| KR20180002640A (ko) | 2018-01-08 |
| IL254957A0 (en) | 2017-12-31 |
| MX2017013174A (es) | 2018-04-11 |
| PH12017502080A1 (en) | 2018-05-07 |
| MA44379A (fr) | 2019-01-23 |
| CN107750256A (zh) | 2018-03-02 |
| AU2016247887A1 (en) | 2017-11-02 |
| HK1250992A1 (zh) | 2019-01-18 |
| UY36616A (es) | 2016-10-31 |
| TW201710285A (zh) | 2017-03-16 |
| US20160346369A1 (en) | 2016-12-01 |
| EA201792274A1 (ru) | 2018-02-28 |
| SV2017005545A (es) | 2018-05-11 |
| WO2016168198A1 (en) | 2016-10-20 |
| ECSP17075380A (es) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17075380A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos | |
| CO2017010807A2 (es) | Enzimas y aplicaciones de las mismas | |
| DOP2018000245A (es) | Proteinas de fusion gdf15 y usos de estas | |
| PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
| MX2021015182A (es) | Casetes optimizados de expresion del gen humano del factor viii de coagulacion y su uso. | |
| UA120917C2 (uk) | Химерний білок фактора viii та його застосування | |
| ES2662801T3 (es) | Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas | |
| BR112019004711A2 (pt) | receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos | |
| ES2531290T3 (es) | Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas | |
| BR112017003406A2 (pt) | genoma de chromobacterium subtsugae | |
| BR112015022491A2 (pt) | variantes de inibidor de tecido de metaloprotease tipo três (timp-3), ácido nucleico isolado, vetor de expressão, célula hospedeira isolada e método para produzir uma muteína de timp-3 recombinante, bem como composição e seu uso | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
| AR102950A1 (es) | Variantes de lipasa y polinucleótidos que las codifican | |
| AR102445A1 (es) | COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| CL2012001380A1 (es) | Composición farmacéutica o cosmética que comprende el polipéptido coriolisina l, las proteínas muy ácidas vapi, vapii, vapiii, y una o más moléculas de ácido nucleico que codifican cualquiera de los polipéptidos recién mencionados; ácido nucleico; vector, célula hospedera; método de preparación de dichos polipéptidos; y método cosmético para exfoliar y/o humectar la piel de un animal. | |
| AR102410A1 (es) | Polipéptidos que tienen actividad xilanasa con una tasa de conversión alta de polisacáridos que contienen xilosa | |
| CO2023003453A2 (es) | Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados | |
| BR112018005464A2 (pt) | expressão de proteínas contendo fc | |
| CU20200064A7 (es) | Expresión de la proteína de superficie neumocócica a (pspa) | |
| AR105615A1 (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos | |
| PE20190967A1 (es) | Aislados modificados de streptomyces fungicidicus y su uso | |
| CU20220017A7 (es) | Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes | |
| AR104231A1 (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer |